{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:25:03Z","timestamp":1767140703353,"version":"build-2238731810"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00393-025-01658-4","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:08:02Z","timestamp":1748239682000},"page":"387-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative Therapieans\u00e4tze in der Rheumatologie","Innovative treatments in rheumatology"],"prefix":"10.1007","volume":"84","author":[{"given":"Abhinav","family":"Singla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Iking-Konert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Kellersmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"10","key":"1658_CR1","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/ard-2024-225800","volume":"83","author":"MG Hren","year":"2024","unstructured":"Hren\u00a0MG, Khattri\u00a0S (2024) Treatment of recalcitrant psoriasis and psoriatic arthritis with a\u00a0combination of a\u00a0biologic plus an oral JAK or TYK2 inhibitor: a\u00a0case series. Ann Rheum Dis 83(10):1392\u20131393","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1658_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler\u00a0ME et\u00a0al (2024) Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 390(10):911\u2013921","journal-title":"N Engl J Med"},{"issue":"8","key":"1658_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"JS Smolen","year":"2022","unstructured":"Smolen\u00a0JS et\u00a0al (2022) Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N\u00a0Engl J Med 387(8):715\u2013726","journal-title":"N Engl J Med"},{"issue":"5","key":"1658_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","volume":"63","author":"A Deodhar","year":"2024","unstructured":"Deodhar\u00a0A et\u00a0al (2024) Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a\u00a0systematic literature review and network meta-analysis. Rheumatology 63(5):1195\u20131205","journal-title":"Rheumatology"},{"issue":"7","key":"1658_CR5","doi-asserted-by":"publisher","first-page":"103612","DOI":"10.1016\/j.drudis.2023.103612","volume":"28","author":"R Felten","year":"2023","unstructured":"Felten\u00a0R et\u00a0al (2023) Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today 28(7):103612","journal-title":"Drug Discov Today"},{"issue":"2","key":"1658_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-024-01474-2","volume":"83","author":"WA Schmidt","year":"2024","unstructured":"Schmidt\u00a0WA (2024) Sarilumab bei Polymyalgia rheumatica. Z\u00a0Rheumatol 83(2):151\u2013152","journal-title":"Z Rheumatol"},{"issue":"2","key":"1658_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728214.2023.2209720","volume":"28","author":"RI Fox","year":"2023","unstructured":"Fox\u00a0RI, Fox\u00a0CM, McCoy\u00a0SS (2023) Emerging treatment for Sj\u00f6gren\u2019s disease: a\u00a0review of recent phase\u00a0II and\u00a0III trials. Expert Opin Emerg Drugs 28(2):107\u2013120","journal-title":"Expert Opin Emerg Drugs"},{"key":"1658_CR8","doi-asserted-by":"crossref","unstructured":"Khanna\u00a0D et\u00a0al (2024) A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In Systemic sclerosis: DAISY study design and rationale. Clin Exp Rheumatol 42(8):1635\u20131644.","DOI":"10.55563\/clinexprheumatol\/s8qcyu"},{"issue":"11","key":"1658_CR9","doi-asserted-by":"publisher","first-page":"0","DOI":"10.17219\/acem\/193892","volume":"34","author":"JA Mastalerz","year":"2025","unstructured":"Mastalerz\u00a0JA et\u00a0al (2025) Novel therapies in SLE treatment: A\u00a0literature review. Adv Clin Exp Med 34(11):0\u20130","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"1658_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"Blair, H.A. and S.T.\u00a0Duggan, Belimumab","year":"2018","unstructured":"Blair, H.A. and S.T.\u00a0Duggan, Belimumab (2018) A\u00a0Review in Systemic Lupus Erythematosus. Drugs 78(3):355\u2013366","journal-title":"Drugs"},{"issue":"1","key":"1658_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","volume":"69","author":"C Gordon","year":"2017","unstructured":"Gordon\u00a0C et\u00a0al (2017) Post hoc analysis of the phase\u00a0II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol 69(1):122\u2013130","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1658_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/13543784.2014.943835","volume":"23","author":"C Richez","year":"2014","unstructured":"Richez\u00a0C et\u00a0al (2014) Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin Investig Drugs 23(9):1285\u20131294","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1658_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2022","unstructured":"Chen\u00a0R et\u00a0al (2022) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a\u00a0real life observational study. Lupus 32(1):94\u2013100","journal-title":"Lupus"},{"key":"1658_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/annrheumdis-2023-eular.1727","volume":"82","author":"L Wang","year":"2023","unstructured":"Wang\u00a0L et\u00a0al (2023) OP0137 Efficacy And Safety Of Telitacicept, A\u00a0Novel Blys\/April Dual Inhibitor, In Patients With Systemic Lupus Erythematosus: A\u00a0Phase 3, Randomized, Placebo-Controlled 52-Week Study. Ann Rheum Dis 82:90\u201391","journal-title":"Ann Rheum Dis"},{"key":"1658_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","volume":"83","author":"JE Gottenberg","year":"2024","unstructured":"Gottenberg\u00a0JE et\u00a0al (2024) LBA0010 efficacy and safety of nipocalimab, an antI-FcRn monoclonal antibody, in primary Sjogren\u2019s disease: results from a\u00a0phase\u00a02, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS). Ann Rheum Dis 83:240","journal-title":"Ann Rheum Dis"},{"key":"1658_CR16","doi-asserted-by":"crossref","unstructured":"Madonna R, Ghelardoni S (2025) Sotatercept in pulmonary hypertension and beyond. Eur J Clin Invest e14386.","DOI":"10.1111\/eci.14386"},{"key":"1658_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/annrheumdis-2024-eular.192","volume":"83","author":"AS Powlesland","year":"2024","unstructured":"Powlesland\u00a0AS et\u00a0al (2024) POS0297 Dapirolizumab Pegol Impacts Important Immunologic Pathways In Systemic Lupus Erythematosus: Pharmacodynamic Analysis Of T Cell And Antigen Presenting Cell Pathways From A Phase 2b Trial. Ann Rheum Dis 83:261","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1658_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12931-024-02888-x","volume":"25","author":"N Vincent-Galti\u00e9","year":"2024","unstructured":"Vincent-Galti\u00e9\u00a0N et\u00a0al (2024) Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma. Respir Res 25(1):272\u2013272","journal-title":"Respir Res"},{"key":"1658_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/annrheumdis-2024-eular.1536","volume":"83","author":"E Jenkins","year":"2024","unstructured":"Jenkins\u00a0E et\u00a0al (2024) OP0036 Efficacy, Safety, And Pharmacokinetics Of Anti-CD40 Antibody Abiprubart (KPL-404) In Patients With Rheumatoid Arthritis: A\u00a0Phase 2, Randomized, Placebo-Controlled 12-Week-Treatment Proof-Of-Concept Study. Ann Rheum Dis 83:81\u201382","journal-title":"Ann Rheum Dis"},{"key":"1658_CR20","unstructured":"Adina KK et\u00a0al (2024) 402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a\u00a0selective plasmacytoid dendritic cell depleter, in a\u00a0phase\u00a02\u00a0trial of patients with moderate-to-severe primary discoid lupus erythematosus. Lupus Sci Med: 2"},{"issue":"12","key":"1658_CR21","first-page":"4905","volume":"61","author":"J Arnold","year":"2022","unstructured":"Arnold\u00a0J et\u00a0al (2022) Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Baillieres Clin Rheumatol 61(12):4905\u20134909","journal-title":"Baillieres Clin Rheumatol"},{"issue":"15","key":"1658_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"A Furie Richard","year":"2025","unstructured":"Furie Richard\u00a0A et\u00a0al (2025) Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N\u00a0Engl J Med 392(15):1471\u20131483","journal-title":"N Engl J Med"},{"key":"1658_CR23","unstructured":"Blockmans D et\u00a0al A\u00a0Phase\u00a03 Trial of Upadacitinib for Giant-Cell Arteritis. N\u00a0Engl J Med 0(0)"},{"issue":"10","key":"1658_CR24","first-page":"1518","volume":"76","author":"JT Merrill","year":"2024","unstructured":"Merrill\u00a0JT et\u00a0al (2024) Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A\u00a0Phase\u00a02 Randomized Controlled Trial. Arthritis Rheumatol 76(10):1518\u20131529","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1658_CR25","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S2665-9913(22)00092-3","volume":"4","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann\u00a0R et\u00a0al (2022) Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a\u00a0multicentre, double-blind, randomised, controlled, phase\u00a02\u00a0trial. Lancet Rheumatol 4(6):e395\u2013e406","journal-title":"Lancet Rheumatol"},{"key":"1658_CR26","unstructured":"Hanson E et\u00a0al Early Development of Ocadusertib, a\u00a0Selective Receptor-Interacting Serine\/Threonine-Protein Kinase 1 Inhibitor. WILEY 111. River St Hoboken: 7030\u20135774 (NJ USA)"},{"issue":"e001563","key":"1658_CR27","first-page":"1","volume":"10","author":"L Richeldi","year":"2023","unstructured":"Richeldi\u00a0L et\u00a0al (2023) Design of a\u00a0phase\u00a0III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Resp Res 10(e001563):1","journal-title":"BMJ Open Resp Res"},{"issue":"e001580","key":"1658_CR28","first-page":"1","volume":"10","author":"TM Maher","year":"2023","unstructured":"Maher\u00a0TM et\u00a0al (2023) Design of a\u00a0phase\u00a0III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Resp Res 10(e001580):1","journal-title":"BMJ Open Resp Res"},{"issue":"2","key":"1658_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand\u00a0E et\u00a0al (2023) Deucravacitinib, a\u00a0Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A\u00a0Phase\u00a0II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 75(2):242\u2013252","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1658_CR30","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/14656566.2024.2373354","volume":"25","author":"A Portarapillo","year":"2024","unstructured":"Portarapillo\u00a0A et\u00a0al (2024) Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert Opin Pharmacother 25(9):1187\u20131198","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1658_CR31","first-page":"2024","volume":"13","author":"O Yilmaz","year":"2024","unstructured":"Yilmaz\u00a0O, Pinto\u00a0JP, Torres\u00a0T (2024) New and emerging oral therapies for psoriasis. DIC 13(6):2024\u20132025","journal-title":"DIC"},{"key":"1658_CR32","unstructured":"Joerg W et\u00a0al (2024) P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase\u00a0Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE\/CLE). Lupus Sci Med: 1"},{"issue":"10416","key":"1658_CR33","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett\u00a0G, Mackensen\u00a0A, Mougiakakos\u00a0D (2023) CAR T\u2011cell therapy in autoimmune diseases. Lancet 402(10416):2034\u20132044","journal-title":"Lancet"},{"issue":"3","key":"1658_CR34","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","volume":"7","author":"K Lungova","year":"2025","unstructured":"Lungova\u00a0K, Putman\u00a0M (2025) Barriers to CAR T\u2011cell therapy in rheumatology. Lancet Rheumatol 7(3):e212\u2013e216","journal-title":"Lancet Rheumatol"},{"key":"1658_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/annrheumdis-2024-eular.3799","volume":"83","author":"R Domingo-Gonzalez","year":"2024","unstructured":"Domingo-Gonzalez\u00a0R et\u00a0al (2024) POS1062 Therapeutic Potential Of Imvotamab, A\u00a0CD20-Targeted Bispecific IGM T CELL Engager, For The Treatment Of Refractory Autoimmune Disease Patients. Ann Rheum Dis 83:935","journal-title":"Ann Rheum Dis"},{"key":"1658_CR36","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1182\/blood-2022-163235","volume":"1","author":"GH Hernandez","year":"2022","unstructured":"Hernandez\u00a0GH et\u00a0al (2022) Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B\u00a0Cell Malignancies. Blood 1:6436\u20136438","journal-title":"Blood"},{"issue":"2","key":"1658_CR37","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/S2665-9913(24)00311-4","volume":"7","author":"J Avouac","year":"2025","unstructured":"Avouac\u00a0J (2025) CD19-targeting CAR-T\u00a0cell treatment in patients with diffuse systemic sclerosis. Lancet Rheumatol 7(2):e74\u2013e75","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1658_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13075-016-1174-z","volume":"18","author":"X Jiang","year":"2016","unstructured":"Jiang\u00a0X et\u00a0al (2016) A\u00a0genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy\u2014results from a\u00a0Swedish cohort study. Arthritis Res Ther 18(1):288\u2013288","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1658_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/gepi.22159","volume":"42","author":"S Cherlin","year":"2018","unstructured":"Cherlin\u00a0S et\u00a0al (2018) Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. Genet Epidemiol 42(8):754\u2013771","journal-title":"Genet Epidemiol"},{"issue":"1","key":"1658_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13073-023-01237-9","volume":"15","author":"EL Hubbard","year":"2023","unstructured":"Hubbard\u00a0EL et\u00a0al (2023) Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications. Genome Med 15(1):84\u201384","journal-title":"Genome Med"},{"issue":"3","key":"1658_CR41","first-page":"1528","volume":"64","author":"R Caorsi","year":"2025","unstructured":"Caorsi\u00a0R et\u00a0al (2025) Long-term efficacy of MAS825, a\u00a0bispecific anti-IL1\u03b2 and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome. Baillieres Clin Rheumatol 64(3):1528\u20131533","journal-title":"Baillieres Clin Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s00393-025-01694-0","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000}}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01658-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01658-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01658-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:18:49Z","timestamp":1757175529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01658-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01658-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"23 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Originalversion wurde korrigiert: W\u00e4hrend der Begutachtung des Beitrags wurde die Zulassung f\u00fcr Upadacitinib erweitert. Dies wurde jedoch in Tab.\u00a01 der Originalversion des Beitrags nicht ber\u00fccksichtigt.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00393-025-01694-0","URL":"https:\/\/doi.org\/10.1007\/s00393-025-01694-0","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"A.\u00a0Singla\n                      : A.\u00a0Finanzielle Interessen: Insmed als Referent f\u00fcr einen Vortrag. \u2013 B.\u00a0Nichtfinanzielle Interessen: Helios Fachklinik Vogelsang-Gommern.\n                      C.\u00a0Iking-Konert\n                      : A.\u00a0Finanzielle Interessen: Abbvie Eular Kongress 2023 und 2023, GSK Eos Summit 2023 und 2024, GSK Eos Reise in HH . \u2013 GSK: Ad Board EGPA und interne Schulung, AstraZeneca : Ad Board EGPA und interne Schulung . \u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt Stadtspital Z\u00fcrich\/Schweiz | Mitgliedschaften: DGRh, SGRh | Medizinischer Berater Swissmedic.\n                      C.\u00a0Kellersmann\n                      : A.\u00a0Finanzielle Interessen: Unterassistentin am Stadtspital Triemli vom 30.12.24 bis zum 30.03.25 . \u2013 B.\u00a0Nichtfinanzielle Interessen: Aktuell Medizinstudentin an der Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf; 30.12.24\u201330.03.25 Unterassistenz in der Abteilung f\u00fcr Rheumatologie am Stadtspital Triemli, Z\u00fcrich | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizi, Deutsche Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e.\u202fV. | Zeitschrift f\u00fcr Rheumatologie.\n                      D.\u00a0Mougiakakos\n                      : A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Gilead, Amgen. \u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Abbvie, AstraZeneca, Beigene, BMS, Gilead, Incyte, Janssen, Kyverna, Miltenyi Biomedicine, Novartis, Roche, Takeda. \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: AstraZeneca, Beigene, BMS, Gilead, Kyverna, Interius, Miltenyi Biomedicine, Roche, Takeda. \u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor, Zentrum f\u00fcr Innere Medizin, Universit\u00e4tsklinik f\u00fcr H\u00e4matologie, Onkologie und Zelltherapie, Otto-von-Guericke-Universit\u00e4t Magdeburg, Medizinische Fakult\u00e4t, Leipziger Str.\u00a044, 39120 Magdeburg.\n                      E.\u00a0Feist\n                      : A.\u00a0Finanzielle Interessen: Honorare f\u00fcr Vortr\u00e4ge und Advisoryboard: Abbvie, AB2Bio, BMS, Celgene, Janssen, Lilly, Medac, Novartis, Pfizer, Roche\/Chugai, Sanofi, Sobi, UCB | . \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Rheumatologe, Chefarzt | Berufsverband Rheumatologie, Vorstandsmitglied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}